Guangzhou Healthquest Pharma

Guangzhou Healthquest Pharma is a clinical-stage biopharmaceutical company based in Guangzhou, China, operating as a core subsidiary of Ascentage Pharma. The company specializes in the discovery and development of innovative small molecule therapies targeting protein-protein interactions (PPIs) to restore programmed cell death (apoptosis) in cancer and other diseases. Its flagship product, olverembatinib (HQP1351), is a third-generation BCR-ABL inhibitor that has received market approval in China for the treatment of tyrosine kinase inhibitor-resistant chronic myeloid leukemia. Beyond oncology, the company is exploring treatments for hepatitis B and age-related conditions. Healthquest Pharma maintains a robust R&D infrastructure and contributes significantly to the global clinical pipeline of its parent company, which includes inhibitors of BCL-2, MDM2-p53, and IAP.